Peptide Radiation Therapy Is Safe and Effective for Neuroendocrine Tumors in Asian Patients
Peptide receptor radionuclide therapy (PRRT) achieved 37.9% response rate with 49-month median progression-free survival and acceptable safety in 107 Asian patients with metastatic neuroendocrine tumors.
Quick Facts
What This Study Found
37.9% partial/complete response rate, 49-month median progression-free survival, with 9% grade 3+ hematological toxicity and 4% grade 3/4 hepatobiliary toxicity in 107 Asian NET patients.
Key Numbers
Data from an Asian center. Previous evidence primarily from US, Europe, and Australia.
How They Did This
Retrospective analysis of 107 patients with metastatic neuroendocrine tumors who underwent PRRT from January 2012 to March 2019, with response assessment using RECIST 1.1 criteria and qualitative analysis.
Why This Research Matters
This is one of the largest Asian PRRT datasets, addressing the evidence gap for this population. Epidemiological differences in NETs between populations make population-specific efficacy data essential for clinical decision-making.
The Bigger Picture
PRRT represents one of the most targeted forms of peptide-based cancer therapy. Confirming its safety and efficacy in diverse populations is essential as the treatment becomes more widely available globally.
What This Study Doesn't Tell Us
Retrospective single-center design; heterogeneous tumor types and grades within the cohort; variable number of treatment cycles; liver metastases confounded hepatobiliary toxicity assessment; no randomized comparator.
Questions This Raises
- ?Are there molecular or genetic factors in Asian NET patients that influence PRRT response differently?
- ?What is the optimal number of PRRT cycles for Asian patients?
- ?How does PRRT compare to other treatments like everolimus or sunitinib in this population?
Trust & Context
- Key Stat:
- 49 months median progression-free survival with PRRT in Asian NET patients
- Evidence Grade:
- Moderate evidence from a reasonably large retrospective cohort, providing important population-specific data despite the lack of a randomized control group.
- Study Age:
- Published in 2024 with data from 2012-2019, providing mature follow-up data on PRRT outcomes.
- Original Title:
- Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.
- Published In:
- Neuroendocrinology, 114(9), 840-847 (2024)
- Authors:
- Tham, Wei Ying(2), Huang, Hian Liang, Tai, David Wai Meng, Allen, John C, Hwang, Jacqueline S G, Loh, Lih Ming, Goh, Brian K P, Ong, Simon Y K, Kek, Peng Chin, Tan, Damien M Y, Ng, David C E, Loke, Kelvin S H
- Database ID:
- RPEP-09378
Evidence Hierarchy
Frequently Asked Questions
What is peptide receptor radionuclide therapy (PRRT)?
PRRT uses small peptides that specifically bind to receptors on neuroendocrine tumor cells. These peptides carry radioactive molecules that deliver targeted radiation directly to the cancer cells, minimizing damage to surrounding healthy tissue.
Does PRRT work as well for Asian patients as it does for Western patients?
Yes — this study's results (37.9% response rate, 49-month progression-free survival) are comparable to Western data, providing reassurance that PRRT is effective across populations despite known epidemiological differences in neuroendocrine tumors.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09378APA
Tham, Wei Ying; Huang, Hian Liang; Tai, David Wai Meng; Allen, John C; Hwang, Jacqueline S G; Loh, Lih Ming; Goh, Brian K P; Ong, Simon Y K; Kek, Peng Chin; Tan, Damien M Y; Ng, David C E; Loke, Kelvin S H. (2024). Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.. Neuroendocrinology, 114(9), 840-847. https://doi.org/10.1159/000538523
MLA
Tham, Wei Ying, et al. "Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.." Neuroendocrinology, 2024. https://doi.org/10.1159/000538523
RethinkPeptides
RethinkPeptides Research Database. "Treatment and Long-Term Safety Outcomes of Peptide Receptor ..." RPEP-09378. Retrieved from https://rethinkpeptides.com/research/tham-2024-treatment-and-longterm-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.